Adding bendamustine and rituximab for stable Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new approach for people with Waldenström macroglobulinemia who have already been on ibrutinib and are doing well but not completely better. It adds two more medicines (bendamustine and rituximab) to see if this combination can achieve a deeper response and allow you to stop treatment after a set period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have been diagnosed with Waldenström macroglobulinemia that has a specific gene change called MYD88 L265P.
- You have been taking ibrutinib for at least 12 rounds, your disease has gotten better but not completely gone, and you are currently stable on this medicine.
- You have not had serious side effects from ibrutinib that required stopping it (no grade 3 or higher side effects).
- You have never been treated with the combination of bendamustine and rituximab (BR).
- Your blood counts and liver and kidney function must be within certain limits (your doctor will check this with blood tests).
- You have not had another cancer (except some skin cancers or early-stage cancers) in the past year, and you do not have serious heart, bleeding, or other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a targeted pill (zanubrutinib) with a lower dose of a chemotherapy drug (bendamustine) and an antibody treatment to see if it works well for people with untreated Waldenström's macroglobulinemia. It aims to reduce side effects while still controlling the disease.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This study is testing a combination of two medicines (zanubrutinib and BR) as the first treatment for patients with Waldenström's macroglobulinemia. The goal is to see if this combination works well and is safe for people who have not been treated before.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
Hear when a new Waldenström Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.